Comparison of Polystemia Vera Patients Diagnosed Before and After the Updated Diagnostic Criteria

Şevket Katılmış; Eren Gunduz

Makale detayları

Comparison of Polystemia Vera Patients Diagnosed Before and After the Updated Diagnostic Criteria

Yazarlar:

Şevket Katılmış | Eren Gunduz

Yayıncı:

Eskişehir Osmangazi University

Ana Başlıklar:

İç Hastalıkları

Dergi:

Osmangazi Tıp Dergisi Vol.46 Issue 3, pp.333-343

Belge Tipi:

Makale

Yayın Tarihi:

5/2024

Belge Dili:

İngilizce

Document ID (Org No.):

2001313502

pISSN:

1305-4953

Anahtar kelimeler:

Özet:

 Polycythemia vera is a chronic, clonal and progressive myeloproliferative disease characterized by leukocytosis, thrombocytosis and splenomegaly with increased erythroid series. In this study, we aimed to compare the clinical and laboratory features of patients diagnosed with PV according to the 2008 and 2016 WHO diagnostic criteria and the complications that developed during follow-up, and to retrospectively evaluate the impact of the change in diagnostic criteria on real life. A total of 100 polycythemia vera patients with positive JAK2-V617F mutation were enrolled in the study, 50 between 2011-2015 and 50 between 2016-2020. When the two groups were compared in terms of laboratory values at the time of diagnosis, hemoglobin, hematocrit and red blood cell count were significantly higher in the group diagnosed before 2016 p0.036. When patients were evaluated for complications of thrombosis, hemorrhage, progression to myelofibrosis, leukemic transformation, and transformation of myelodysplastic syndrome at last follow-up, it was found that 19 38 patients in the pre-2016 group and 5 10 patients in the post-2016 group developed complications p0.002. The number of patients who developed a myelofibrosis complication was significantly higher in the pre-2016 group p0.006. The number of patients who developed thrombosis was higher in the pre-2016 group, but the difference did not reach a statistically significant level p0.055. About other complications, there was no difference between the two groups p  0.05. In summary, our study found a significant difference only in the number of patients with myelofibrosis complications. Further studies with more patients will be needed to determine the impact of the 2016 change in diagnostic criteria on other complications.

 Polycythemia vera is a chronic, clonal and progressive myeloproliferative disease characterized by leukocytosis, thrombocytosis and splenomegaly with increased erythroid series. In this study, we aimed to compare the clinical and laboratory features of patients diagnosed with PV according to the 2008 and 2016 WHO diagnostic criteria and the complications that developed during follow-up, and to retrospectively evaluate the impact of the change in diagnostic criteria on real life. A total of 100 polycythemia vera patients with positive JAK2-V617F mutation were enrolled in the study, 50 between 2011-2015 and 50 between 2016-2020. When the two groups were compared in terms of laboratory values at the time of diagnosis, hemoglobin, hematocrit and red blood cell count were significantly higher in the group diagnosed before 2016 p0.036. When patients were evaluated for complications of thrombosis, hemorrhage, progression to myelofibrosis, leukemic transformation, and transformation of myelodysplastic syndrome at last follow-up, it was found that 19 38 patients in the pre-2016 group and 5 10 patients in the post-2016 group developed complications p0.002. The number of patients who developed a myelofibrosis complication was significantly higher in the pre-2016 group p0.006. The number of patients who developed thrombosis was higher in the pre-2016 group, but the difference did not reach a statistically significant level p0.055. About other complications, there was no difference between the two groups p  0.05. In summary, our study found a significant difference only in the number of patients with myelofibrosis complications. Further studies with more patients will be needed to determine the impact of the 2016 change in diagnostic criteria on other complications.

 Polycythemia vera is a chronic, clonal and progressive myeloproliferative disease characterized by leukocytosis, thrombocytosis and splenomegaly with increased erythroid series. In this study, we aimed to compare the clinical and laboratory features of patients diagnosed with PV according to the 2008 and 2016 WHO diagnostic criteria and the complications that developed during follow-up, and to retrospectively evaluate the impact of the change in diagnostic criteria on real life. A total of 100 polycythemia vera patients with positive JAK2-V617F mutation were enrolled in the study, 50 between 2011-2015 and 50 between 2016-2020. When the two groups were compared in terms of laboratory values at the time of diagnosis, hemoglobin, hematocrit and red blood cell count were significantly higher in the group diagnosed before 2016 p0.036. When patients were evaluated for complications of thrombosis, hemorrhage, progression to myelofibrosis, leukemic transformation, and transformation of myelodysplastic syndrome at last follow-up, it was found that 19 38 patients in the pre-2016 group and 5 10 patients in the post-2016 group developed complications p0.002. The number of patients who developed a myelofibrosis complication was significantly higher in the pre-2016 group p0.006. The number of patients who developed thrombosis was higher in the pre-2016 group, but the difference did not reach a statistically significant level p0.055. About other complications, there was no difference between the two groups p  0.05. In summary, our study found a significant difference only in the number of patients with myelofibrosis complications. Further studies with more patients will be needed to determine the impact of the 2016 change in diagnostic criteria on other complications.

 Polisitemia vera, eritroid serilerde artışla birlikte lökositoz, trombositoz ve splenomegali ile karakterize kronik, klonal ve ilerleyici bir miyeloproliferatif hastalıktır. Bu çalışmada, 2008 ve 2016 DSÖ tanı kriterlerine göre PV tanısı alan hastaların klinik ve laboratuvar özellikleri ile takip sırasında gelişen komplikasyonları karşılaştırmayı ve tanı kriterlerindeki değişikliğin gerçek hayata etkisini retrospektif olarak değerlendirmeyi amaçladık. Çalışmaya 2011-2015 yılları arasında 50 ve 2016-2020 yılları arasında 50 olmak üzere JAK2-V617F mutasyonu pozitif olan toplam 100 polisitemia vera hastası dahil edilmiştir. İki grup tanı anındaki laboratuvar değerleri açısından karşılaştırıldığında, hemoglobin, hematokrit ve kırmızı kan hücresi sayısı 2016dan önce tanı alan grupta anlamlı olarak daha yüksekti p0,036. Hastalar son takipte tromboz, kanama, miyelofibrozise ilerleme, lösemik dönüşüm ve miyelodisplastik sendroma dönüşüm komplikasyonları açısından değerlendirildiğinde, 2016 öncesi grupta 19 38 hastada, 2016 sonrası grupta ise 5 10 hastada komplikasyon geliştiği tespit edilmiştir p0,002. Miyelofibrozis komplikasyonu gelişen hasta sayısı 2016 öncesi grupta anlamlı olarak daha yüksekti p0,006. Tromboz gelişen hasta sayısı 2016 öncesi grupta daha yüksekti, ancak fark istatistiksel olarak anlamlı düzeye ulaşmadı p0,055. Diğer komplikasyonlar açısından iki grup arasında fark bulunmamıştır p  0,05. Özet olarak, çalışmamızda sadece miyelofibrozis komplikasyonu görülen hasta sayısında anlamlı bir fark bulunmuştur. Tanı kriterlerinde 2016da yapılan değişikliğin diğer komplikasyonlar üzerindeki etkisini belirlemek için daha fazla hasta ile daha ileri çalışmalara ihtiyaç duyulacaktır.

Makale detayları

Comparison of Polystemia Vera Patients Diagnosed Before and After the Updated Diagnostic Criteria

Yazarlar:

Şevket Katılmış | Eren Gunduz

Yayıncı:

Eskişehir Osmangazi University

Ana Başlıklar:

İç Hastalıkları

Dergi:

Osmangazi Tıp Dergisi Vol.46 Issue 3, pp.333-343

Belge Tipi:

Makale

Yayın Tarihi:

5/2024

Belge Dili:

İngilizce

Document ID (Org No.):

2001313502

pISSN:

1305-4953

Polystemia vera

Diagnosis

Treatment

ComplicationsPolistemia vera

Tanı

Tedavi

Komplikasyon

Sayı

Makale detayları

Yazarlar: Şevket Katılmış | Eren Gunduz

Yayıncı: Eskişehir Osmangazi University

Ana Başlıklar: İç Hastalıkları

Dergi: Osmangazi Tıp Dergisi Vol.46 Issue 3, pp.333-343

Belge Tipi: Makale

Yayın Tarihi: 5/2024

Belge Dili: İngilizce

Document ID (Org No.): 2001313502

pISSN: 1305-4953

Sayı

Yazarlar:

Şevket Katılmış | Eren Gunduz

Yayıncı:

Eskişehir Osmangazi University

Ana Başlıklar:

İç Hastalıkları

Dergi:

Osmangazi Tıp Dergisi Vol.46 Issue 3, pp.333-343

Belge Tipi:

Makale

Yayın Tarihi:

5/2024

Belge Dili:

İngilizce

Document ID (Org No.):

2001313502

pISSN:

1305-4953